advertising
Even as the economy trends downward, restauranteurs bet our hunger for red meat will grow
From industry to the military to pleasure, Washington boat makers meet a variety of needs
Cascade land conservancy's Gene Duvernoy focuses on practical solutions to preserve land
Horse raising becomes less cost-effective in an economic downturn
Who should we look to for leadership in business and government?
Flip: How to Turn Everything You Know on Its Head -- and Succeed Beyond Your Wildest Imaginings
By...
How to present like a pro, even if it doesn't come naturally
A new biotechnology company being launched out of Accelerator Corp., a business incubator in Seattle, is seeking to commercialize technology developed at Washington State University. Commercializing university research is not unusual for a start-up, except that this time, the biotech coming out of Pullman is expected to lead to cancer treatment for humans. This is a first for the landgrant university, whose traditional areas of expertise are in agricultural, veterinary and bioenergy sciences rather than human-based biomedical science. The technology is expected to yield therapies that arrest the spread of cancerous tumors. Research director for the start-up company, Recodagen, will be J. Suzanne Lindsey, the WSU researcher who first developed the technology. Recodagen has raised an undisclosed amount of initial seed funding, making it the first venture-funded start-up to come out of WSU's technology licensing program.
Print
Email